Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WGI-0301 Plus Lenvatinib in Advanced Hepatocellular Carcinoma
NCT07540832Phase 2Not yet recruiting
- Sponsor
- Haichang Biotech
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Modality
- Modified DNA Oligonucleotides, Lipid-based Nanoparticles, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of WGI-0301 in hepatocellular carcinoma (HCC), sponsored by Haichang Biotech. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
WGI-0301
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07540832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07540832.